Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States

Published:2019-05-17 Issue:10 Volume:22 Page:981-993
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Bensimon Arielle G.¹,Zhou Zheng-Yi²,Jenkins Madeline²,Song Yan¹,Gao Wei¹,Signorovitch James¹,Krepler Clemens³,Liu Frank Xiaoqing³,Wang Jingshu³,Aguiar-Ibáñez Raquel⁴

Affiliation:

1. Analysis Group Inc., Boston, MA, USA;

2. Analysis Group Inc., London, United Kingdom;

3. Merck & Co. Inc., Kenilworth, NJ, USA;

4. Merck Sharp and Dohme BV, Harleem, The Netherlands

Funder

Merck Sharp & Dohme Corp

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2019.1609485

Reference75 articles.

1. National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer stat facts: melanoma of the skin; [cited 2018 Oct 30]. Available from: https://seer.cancer.gov/statfacts/html/melan.html

2. American Cancer Society. Survival Rates for Melanoma; 2016 [cited 2018 October 31]. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html

3. Stone M. Surgical management of metastatic melanoma: UpToDate; 2016 [cited 2018 October 30]. Available from: https://www.uptodate.com/contents/surgical-management-of-metastatic-melanoma

4. Mayo Clinic. Melanoma diagnosis and treatment 2016 [cited 2018 October 31]. Available from: https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy;Clinical Drug Investigation;2024-08

3. Economic Evaluation of Neoadjuvant Versus Adjuvant Chemotherapy in Cancer Treatment: A Systematic Review and Meta-Analysis;Value in Health Regional Issues;2024-05

4. Application of multistate modeling to clinical data analysis;CPT: Pharmacometrics & Systems Pharmacology;2024-02-12

5. Age-stratified comparison of active surveillance versus radiofrequency ablation for papillary thyroid microcarcinoma using decision analysis;Surgery;2024-01